Baseline multimodal clinical-radiomics-pathomics model predicts mucosal healing in Crohn’s disease after infliximab therapy

Table 2 Clinical factors in the training and testing sets, mean ± SD

Clinical factors	Ileal (n = 102)			Ileocolonic (n = 167)
	Train (n = 71)	Test (n = 31)	P value	Train (n = 116)	Test (n = 51)	P value
Gender			0.387			0.989
Male	56	22		82	36
Female	15	9		34	15
Age at CD diagnosis (year), median IQR	28 (20-38)	30 (21-35)	0.951	24 (19-31)	27 (20-39)	0.126
Disease duration (day), median IQR	5 (2-23)	5 (1-58)	0.835	4 (2-16.75)	3 (1-15)	0.446
CRP at baseline (mg/L), median IQR	5.27 (2.17-17.06)	4.6 (1.30-19.91)	0.991	13.29 (3.19-36.30)	9.49 (4.25-25.20)	0.541
ESR at baseline (mm/hour), median IQR	16.25 (12.00-25.00)	22.00 (7.00-36.00)	0.555	30.40 (17.63-43.75)	16.00 (11.50-31.00)	< 0.001
WBC at baseline (× 109/L)	6.32 ± 2.09	6.31 ± 2.29	0.977	7.34 ± 2.23	6.46 ± 1.78	0.02
Alb at baseline (g/L)	39.66 ± 4.61	38.65 ± 4.73	0.313	37.68 ± 5.88	37.36 ± 4.79	0.74
FC at baseline (μg/g), median IQR	762.58 (394.78-1085.72)	774.94 (429.66-1137.76)	0.952	1086.68 (850.76-1335.94)	1019.20 (798.78-1263.00)	0.078
Perianal involvement			0.641			0.667
-	40	19		45	18
+	31	12		71	33
Smoking status at diagnosis			0.858			0.46
-	64	29		115	49
+	7	2		1	2
Previous steroids or immunomodulators use			0.858			0.478
0	46	21		82	32
1	21	9		26	16
2	4	1		8	3
Montreal behavior			0.355			0.811
Nonstricturing, nonpenetrating (B1)	47	20		98	41
Stricturing (B2)	7	6		11	6
Penetrating (B3)	17	5		7	4
HBI at baseline, median IQR	2 (1-4)	2 (1-5)	0.28	4 (1-6)	3 (1-5)	0.425
MH			0.871			0.971
MH	31	13		39	17
Non-MH	40	18		77	34

CD: Crohn’s disease; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; IQR: Interquartile range; Alb: Albumin; FC: Fecal calprotectin; WBC: White blood cell; HBI: Harvey-Bradshaw index; MH: Mucosal healing.